Hormones · Melatonin

Taxifolin modulates circadian protein expression comparable to melatonin in cellular models of mood disorders

Taxifolin, identified via virtual screening of ~150,000 natural compounds against the Melatonin 1 receptor (MT1), showed high binding affinity (-9.527 kcal/mol) and stable protein-ligand complexes in molecular dynamics simulations. Immunocytochemistry analysis revealed that taxifolin modulated circadian regulators CLOCK and BMAL1 expression in a manner similar to melatonin, suggesting potential as a natural neuromodulator for mood disorders.

1 min read•Updated Jul 7, 2026•0 RCTs•View structured evidence →
Evidence Score24/100
Human RCT☆☆☆☆☆
Meta-analysis☆☆☆☆☆
Mechanism☆☆☆☆☆
Safety☆☆☆☆☆
Confidencelow

This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.

Taxifolin modulates circadian protein expression comparable to melatonin in cellular models of mood disorders The current body of evidence comprises 1 study. EvidenceHub rates the overall confidence at 24/100 (low).

The Claim

Taxifolin modulates circadian protein expression comparable to melatonin in cellular models of mood disorders

This conclusion is most relevant to: In silico models and cellular immunocytochemistry assays (no human subjects).

What the Research Shows

The conclusion draws on 1 linked study. Highlights from the cited literature:

  • ▸Integrative network pharmacology and molecular modelling identify taxifolin as a potential modulator of melatonin receptor MT1 in mood disorders. (Molecular diversity, 2026) —

How It Works

The proposed biological pathway:

  • ▸Taxifolin binds to melatonin receptor MT1 with high affinity (-9.527 kcal/mol)
  • ▸Forms stable protein-ligand complexes with sustained hydrogen bonding and reduced fluctuations
  • ▸Modulates circadian protein expression (CLOCK, BMAL1) in cells
  • ▸Suggests stabilization of melatonergic signaling and circadian rhythm regulation

Who Might Benefit

Evidence fit by population:

  • ▸In silico models and cellular immunocytochemistry assays (no human subjects)

Limitations & Caveats

Important context when interpreting this evidence:

  • ▸Study is primarily computational and in vitro; no in vivo or clinical validation provided
  • ▸Immunocytochemistry data are preliminary and lack quantitative effect sizes or statistical comparisons

References

  1. 1.Bartwal SS, Chhabra V, Rai A, Murti K, Kumar N. “Integrative network pharmacology and molecular modelling identify taxifolin as a potential modulator of melatonin receptor MT1 in mood disorders..” Molecular diversity, 2026. PMID: 42377825 DOI: 10.1007/s11030-026-11630-2
Disclaimer: This article is auto-generated from structured research data for educational purposes only and is not medical advice. Evidence scores reflect the quality and quantity of available research, not clinical recommendations. Always consult a healthcare professional before starting any supplement or intervention.